Nordlander M, Thalén P
J Cardiovasc Pharmacol. 1987;10 Suppl 1:S100-6. doi: 10.1097/00005344-198710001-00019.
Arterial vascular resistance is established by myogenic mechanisms and is modulated both by local factors such as vasodilator metabolites and by remote controls of neurogenic and hormonal origin. This paper reports on the effects of felodipine and hydralazine on the myogenic tone and the neurogenic control of the vascular resistance of skeletal muscle. The vascular bed of the calf muscle of anesthetized cats was isolated and autoperfused at a constant flow. The sympathetic vasomotor nerves were activated by efferent stimulation of the lumbar sympathetic chain. Intraarterial infusion of felodipine and hydralazine reduced, in a dose-dependent manner, basal vascular resistance determined by myogenic factors and the vasoconstriction induced by nerve stimulation. After the infusion of felodipine, the vasoconstrictor responses to low, physiological rates of stimulation (0.5-4 Hz) were depressed to the same relative extent as resistance determined by myogenic factors, whereas the vasoconstrictor responses to supramaximal stimulation rates (16-32 Hz) were relatively more resistant. Felodipine had no effect on noradrenaline (NA) release during vasomotor nerve stimulation as determined by the NA venoarterial concentration difference. Hydralazine also reduced basal vascular resistance in a dose-dependent manner, but in contrast to felodipine, supramaximal doses of hydralazine totally abolished vasoconstrictor responses to supramaximal stimulation rates (32 Hz). It is concluded that felodipine reduces vascular resistance by a direct action on the contraction of vascular smooth muscle in the resistance vessels, as myogenic activity and physiological levels of neurogenic vasoconstriction are equally suppressed by felodipine. During supramaximal stimulation of vasomotor nerves, a separate activation pathway or more proximal vascular segments are likely to be engaged that are less sensitive to felodipine.
动脉血管阻力由肌源性机制确立,并受到局部因素(如血管舒张代谢产物)以及神经源性和激素源性远程控制的调节。本文报道了非洛地平和肼屈嗪对骨骼肌血管阻力的肌源性张力和神经源性控制的影响。将麻醉猫小腿肌肉的血管床分离并以恒定流量进行自身灌注。通过腰交感神经链的传出刺激激活交感血管运动神经。动脉内输注非洛地平和肼屈嗪以剂量依赖性方式降低了由肌源性因素决定的基础血管阻力以及神经刺激诱导的血管收缩。输注非洛地平后,对低生理刺激频率(0.5 - 4 Hz)的血管收缩反应与由肌源性因素决定的阻力降低到相同的相对程度,而对超最大刺激频率(16 - 32 Hz)的血管收缩反应相对更具抗性。通过去甲肾上腺素动静脉浓度差测定,非洛地平对血管运动神经刺激期间的去甲肾上腺素(NA)释放没有影响。肼屈嗪也以剂量依赖性方式降低基础血管阻力,但与非洛地平不同的是,超最大剂量的肼屈嗪完全消除了对超最大刺激频率(32 Hz)的血管收缩反应。结论是非洛地平通过直接作用于阻力血管中的血管平滑肌收缩来降低血管阻力,因为非洛地平同等程度地抑制了肌源性活动和神经源性血管收缩的生理水平。在血管运动神经的超最大刺激期间,可能涉及一个单独的激活途径或更靠近近端的血管段,它们对非洛地平不太敏感。